sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients

Journal of Experimental & Clinical Cancer Research

Roman A. Blaheta⁴  Axel Haferkamp⁴  Karen Nelson³  Hanns Ackermann¹  Elsie Oppermann²  Georg Bartsch⁴  Rene Mager⁴  Hendrik Borgmann⁴  Kilian M. Gust⁴  Eva Juengel⁴  Kristina Thurn⁴  Igor Tsaur⁴ 

[1] Institute for Biostatistics, Goethe-University, Frankfurt am Main, Germany;Department of Surgery, Goethe-University, Frankfurt am Main, Germany;Department of Vascular and Endovascular Surgery, Goethe-University, Frankfurt am Main, Germany;Department of Urology, Goethe-University, Frankfurt am Main, Germany

关键词: sE-cadherin;    Biomarker;    Prediction;    Diagnosis;    Prostate cancer;   

Others  :  1220705
DOI  :  10.1186/s13046-015-0161-6

 received in 2015-02-16, accepted in 2015-05-01,  发布年份 2015

【 摘 要 】

Background

Measurement of prostate-specific antigen (PSA) advanced the diagnostic and prognostic potential for prostate cancer (PCa). However, due to PSA’s lack of specificity, novel biomarkers are needed to improve risk assessment and ensure optimal personalized therapy. A set of protein molecules as potential biomarkers was therefore evaluated in serum of PCa patients.

Methods

Serum samples from patients undergoing radical prostatectomy (RPE) for biopsy-proven PCa without neoadjuvant treatment were compared to serum samples from healthy subjects. Preliminary screening of 119 proteins in 10 PCa patients and 10 controls was carried out by the Proteome Profiler Antibody Array. Those markers showing distinct differences between patients and controls were then further evaluated by ELISA in the serum of 165 PCa patients and 19 controls. Uni- and multivariate as well as correlation analysis were performed to test the capability of these molecules to detect disease and predict pathological outcome.

Results

Screening showed that soluble (s)E-cadherin, E-selectin, MMP2, MMP9, TIMP1, TIMP2, Galectin and Clusterin warranted further evaluation. sE-Cadherin, TIMP1, Galectin and Clusterin were significantly over- and MMP9 under-expressed in PCa compared to controls. The concentration of sE-cadherin, MMP2 and Clusterin correlated negatively and that of MMP9 and TIMP1 positively with the Gleason Sum at prostatectomy. Only sE-cadherin significantly correlated with the highest Gleason pattern. Compared to serum PSA, sE-cadherin provided an independent and better matching predictive ability for discriminating PCas with an upgrade at RPE and aggressive tumors with a Gleason Sum ≥7.

Conclusions

sE-cadherin performed most favorably from a large panel of serum proteins in terms of diagnostic and predictive potential in curatively treatable PCa. sE-cadherin merits further investigation as a biomarker for PCa.

【 授权许可】

   
2015 Tsaur et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Shafique K, Oliphant R, Morrison DS: The impact of socio-economic circumstances on overall and grade-specific prostate cancer incidence: a population-based study. Br J Cancer 2012, 107:575-82.
• [2]Roehrborn CG, Black LK: The economic burden of prostate cancer. BJU Int 2011, 108:806-13.
• [3]Joniau S, Pfister D, de la Taille A, Gaboardi F, Thompson A, Ribal MJ: Controversies on individualized prostate cancer care: gaps in current practice. Ther Adv Urol 2013, 5:233-44.
• [4]Adami HO: The prostate cancer pseudo-epidemic. Acta Oncol 2010, 49:298-304.
• [5]Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al.: EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014, 65:124-37.
• [6]Caras RJ, Sterbis JR: Prostate cancer nomograms: a review of their use in cancer detection and treatment. Curr Urol Rep 2014, 15:391.
• [7]Freedland S, Mithal P: Editorial comment. Urology 2013, 81:1208.
• [8]Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M et al. CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study. Cancer Res Treat. 2014; doi:10.4143/crt.2014.015.
• [9]Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, et al.: Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol 2014, 191:1132-8.
• [10]Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albini A, et al.: Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. Cancer Metastasis Rev 2014, 33:657-71.
• [11]Edge SB: American joint committee on cancer., american cancer society., Teton data systems (firm). AJCC cancer staging handbook from the AJCC cancer staging manual. 7th ed. Springer, New York; 2010.
• [12]Wittekind C: International union against cancer. TNM-klassifikation maligner tumoren. 6. Aufl., korrig. Nachdr. ed. Springer Medizin, Heidelberg; 2005.
• [13]Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG: The 2005 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29:1228-42.
• [14]D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-74.
• [15]Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al.: EAU guidelines on prostate cancer. Eur Urol 2008, 53:68-80.
• [16]Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, et al.: Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014, 65:534-42.
• [17]Vittinghoff E, McCulloch CE: Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007, 165:710-8.
• [18]David JM, Rajasekaran AK: Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Res 2012, 72:2917-23.
• [19]Halbleib JM, Nelson WJ: Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 2006, 20:3199-214.
• [20]van Roy F, Berx G: The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008, 65:3756-88.
• [21]Gheldof A, Berx G: Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci 2013, 116:317-36.
• [22]De Freitas Silva BS, Yamamoto-Silva FP, Pontes HA, Pinto Junior Ddos S: E-cadherin downregulation and Twist overexpression since early stages of oral carcinogenesis. J Oral Pathol Med. 2014, 43:125-31.
• [23]Repetto O, De Paoli P, De Re V, Canzonieri V, Cannizzaro R: Levels of soluble E-cadherin in breast, gastric, and colorectal cancers. Biomed Res Int 2014, 2014:408047.
• [24]Ahmed MI, Abd-Elmotelib F, Farag RM, Ziada NA, Khalifa A: Evaluation of some tissue and serum biomarkers in prostatic carcinoma among Egyptian males. Clin Biochem 1999, 32:439-45.
• [25]Danneman D, Drevin L, Robinson D, Stattin P, Egevad L: Gleason inflation 1998-2011: a registry study of 97 168 men. BJU Int 2015, 115:248-55.
• [26]Kuefer R, Hofer MD, Gschwend JE, Pienta KJ, Sanda MG, Chinnaiyan AM, et al.: The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. Clin Cancer Res 2003, 9:6447-52.
• [27]Iacopino F, Pinto F, Bertaccini A, Calarco A, Proietti G, Totaro A, et al.: Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy. Oncol Rep 2012, 28:370-4.
• [28]Epstein JI: An update of the Gleason grading system. J Urol 2010, 183:433-40.
• [29]D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al.: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995, 154:131-8.
• [30]Juhasz M, Ebert MP, Schulz HU, Rocken C, Molnar B, Tulassay Z, et al.: Dual role of serum soluble E-cadherin as a biological marker of metastatic development in gastric cancer. Scand J Gastroenterol 2003, 38:850-5.
• [31]Grabowska MM, Day ML: Soluble E-cadherin: more than a symptom of disease. Front Biosci (Landmark Ed) 2012, 17:1948-64.
• [32]Gumbiner BM: Regulation of cadherin adhesive activity. J Cell Biol 2000, 148:399-404.
• [33]Parrish AR, Catania JM, Orozco J, Gandolfi AJ: Chemically induced oxidative stress disrupts the E-cadherin/catenin cell adhesion complex. Toxicol Sci 1999, 51:80-6.
• [34]Kallakury BV, Sheehan CE, Ross JS: Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol 2001, 32:849-55.
• [35]Yoshida GJ, Saya H: Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun 2014, 443:622-7.
• [36]Lein M, Jung K, Weiss S, Schnorr D, Loening SA: Soluble CD44 variants in the serum of patients with urological malignancies. Oncology 1997, 54:226-30.
• [37]Tei H, Miyake H, Harada K, Fujisawa M: Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy. Urol Oncol 2014, 32:694-700.
• [38]Rupp AK, Rupp C, Keller S, Brase JC, Ehehalt R, Fogel M, et al.: Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol Oncol 2011, 122:437-46.
• [39]Yoshida GJ, Saya H: EpCAM expression in the prostate cancer makes the difference in the response to growth factors. Biochem Biophys Res Commun 2014, 443:239-45.
• [40]Biswas MH, Du C, Zhang C, Straubhaar J, Languino LR, Balaji KC: Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer. Cancer Res 2010, 70:2095-104.
• [41]Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT, et al.: Age and Racial Differences among PSA-Detected (AJCC Stage T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men. Front. Oncol 2013, 3:312.